Daiichi Sankyo Buys Out China Shell Company To Breathe New Life Into Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
While Daiichi Sankyo has relied on Ranbaxy's sales presence in other emerging markets, it has decided to buy a stake in China to give Ranbaxy's portfolio a second chance in the country.